Radiopharmaceutical Targets & Uptake Mechanisms
Mechanism → target → clinical and theranostic consequence
Quick Answer
A radiopharmaceutical's behavior — where it goes, what it means, and whether it can be paired with a therapeutic isotope — follows from its uptake mechanism and molecular target. Grouping tracers by mechanism (metabolic trapping, active transport, receptor binding, physical microembolization, chemisorption, blood-pool retention) makes their normal biodistribution, characteristic artifacts, and theranostic potential predictable rather than memorized. This page organizes the atlas's tracers by mechanism and draws the clinical consequence of each.
Why Mechanism Predicts Everything Downstream
The same property that produces the signal produces the physiologic biodistribution (hence the normal-variant "mimics"), the labeling-failure pattern, and the eligibility logic for therapy. A tracer taken up by the sodium-iodide symporter images the thyroid and free pertechnetate lands in stomach/salivary tissue and the therapeutic isotope of the same handling (I-131) treats iodine-avid disease — one mechanism, three consequences.
Metabolic Trapping
| Tracer | Mechanism / target | Clinical consequence |
|---|---|---|
| FDG | GLUT transport + hexokinase phosphorylation (trapped as FDG-6-P) | Broad oncology/inflammation/viability; hyperglycemia competes; well-differentiated HCC clears it (G6Pase) |
| N-13-ammonia | Diffusion + metabolic trapping (glutamine synthetase) | Cardiac PET perfusion; high, flow-stable extraction |
| NaF | Fluoride–hydroxyl exchange in hydroxyapatite | Bone PET; images bone reaction, not tumor |
Active Transport
| Tracer | Mechanism / target | Clinical consequence |
|---|---|---|
| Radioiodine (I-123/131) | NIS trapping + organification | Thyroid imaging/therapy; the original theranostic; MTC (no NIS) fails |
| Pertechnetate | NIS trapping only (no organification); gastric/salivary uptake | Thyroid trapping, Meckel, salivary; its map = the free-pertechnetate artifact |
| MIBG | Norepinephrine transporter (uptake-1), vesicular storage | Pheo/para, neuroblastoma; drug interference; theranostic with I-131-MIBG |
| Sestamibi / tetrofosmin | Potential-driven diffusion → mitochondrial retention | MPI (flow) and parathyroid (mitochondria-rich adenoma); P-gp efflux |
| Thallium-201 / Rb-82 | K⁺ analog via Na⁺/K⁺-ATPase | Viability (Tl redistribution); cardiac PET (Rb); extraction falls at high flow |
| MAG3 | Tubular secretion (OAT) — high extraction | Dynamic renography; images well in poor function |
| DTPA | Glomerular filtration (no secretion/reabsorption) | True GFR marker; poor images in CKD |
| DMSA | Proximal-tubular cortical binding/retention | Cortical map (scars, split function) |
| FDOPA | LAT amino-acid transport + AADC decarboxylation | Pheo/para, NET, glioma, striatum |
| Fluciclovine | Amino-acid transport (ASCT2/LAT1) | Prostate recurrence (low urinary excretion) |
Receptor / Antigen Binding
| Tracer | Target | Clinical / theranostic consequence |
|---|---|---|
| DOTATATE | SSTR2 | NET imaging → ¹⁷⁷Lu-DOTATATE; physiologic spleen/adrenal/pituitary/uncinate |
| PSMA ligands | GCPII/FOLH1 (tumor cells; neovascular in RCC) | Prostate imaging → ¹⁷⁷Lu-PSMA; salivary/renal/ganglion uptake |
| FES | Estrogen receptor | Whole-body ER phenotyping; ER-blocker false-negatives |
| FAPI | Fibroblast activation protein (stroma) | FDG-low/desmoplastic tumors; low liver/brain background |
| Ioflupane | Presynaptic dopamine transporter (DAT) | Deficit (not disease); normal excludes degenerative parkinsonism |
| Amyloid ligands | β-pleated-sheet plaque | Negative excludes AD amyloid; positive rises with age |
| Tau ligands | Paired-helical-filament tau | Tracks stage/topography better than amyloid |
| Girentuximab | CAIX (ccRCC) | ⁸⁹Zr characterization (ZIRCON) → ¹⁷⁷Lu (investigational) |
| Anti-CD20 (ibritumomab) | CD20 (B cells) | Radioimmunotherapy; crossfire kills antigen-negative neighbors |
Physical / Compartmental Mechanisms
| Tracer | Mechanism | Clinical consequence |
|---|---|---|
| MAA | Capillary microembolization (particle > capillary) | Lung perfusion; Y-90 simulation/lung-shunt gate; R-to-L shunt → systemic activity |
| Sulfur colloid | RES phagocytosis (size-dependent) | Liver/spleen (large), marrow/lymphatic (small/filtered); colloid shift |
| Labeled RBC | Intravascular blood-pool retention | MUGA, hemangioma fill-in, GI bleed (appears-and-moves) |
| Labeled WBC | Neutrophil chemotaxis to infection | Infection (± marrow scan for the incongruence rule) |
| HMPAO / ECD | Lipophilic BBB crossing → intracellular fixation | Perfusion "snapshot" at injection (ictal SPECT, brain death) |
| MDP / HDP | Chemisorption to hydroxyapatite | Osteoblastic bone reaction (sensitive, not specific) |
| PYP | Binds amyloid-associated microcalcification | ATTR cardiac amyloid (monoclonal screen + SPECT) |
| Ga-67 | Transferrin/lactoferrin at inflammation/tumor | Legacy infection/sarcoid/lymphoma |
The Theranostic Corollary
A mechanism is a theranostic pair when the same targeting handling can carry a diagnostic and a therapeutic isotope: NIS (I-123 → I-131), SSTR2 (Ga-68-DOTATATE → ¹⁷⁷Lu-DOTATATE), PSMA (Ga-68/¹⁸F → ¹⁷⁷Lu/²²⁵Ac), NET/uptake-1 (I-123-MIBG → I-131-MIBG), CD20 (antibody + ⁹⁰Y), and — emerging — CAIX (⁸⁹Zr → ¹⁷⁷Lu-girentuximab) and FAP. The DOTA chelator is what makes the metal-based pairs interchangeable at near-identical biodistribution.
The Artifact Corollary
A tracer's normal biodistribution is its artifact list. Free-pertechnetate labeling failures reproduce the NIS/gastric/salivary map; DOTATATE's physiologic uncinate/spleen/adrenal/pituitary uptake mimics tumor; PSMA's celiac ganglion/salivary/renal uptake mimics nodes; MAA's clumping or a right-to-left shunt sends activity systemically. Knowing the mechanism is knowing the false positive.
The Extraction & Kinetics Corollary
Mechanism sets quantitative behavior: high-extraction tubular MAG3 images poor kidneys where filtered DTPA fails; Rb-82/Tl extraction falls at high flow (a kinetic-modeling correction in MFR); sestamibi/HMPAO show minimal redistribution (flexible timing / injection-snapshot), unlike thallium (redistribution = viability). These are not trivia — they determine which agent answers a given question.
Related Pages
- Foundational: Molecular imaging & the theranostic pair, radiopharmaceuticals & production, physics of nuclear medicine.
- Applied: the individual tracer pages linked from each row.
Figure / Diagram Suggestions
- A mechanism → biodistribution → artifact → theranostic four-column synthesis.
- A theranostic-pair ladder (target → diagnostic isotope → therapeutic isotope).
Self-Check
Q1. Why does the free-pertechnetate artifact appear in the thyroid, stomach, and salivary glands?
Answer: Pertechnetate is handled by the sodium-iodide symporter (trapping) and concentrated by gastric/salivary tissue — so unbound Tc-99m reproduces that physiologic map on any poorly-labeled study.
Q2. A tumor is DOTATATE-negative but FDG-avid. What does the mechanism mismatch imply for therapy?
Answer: Loss of the SSTR2 target with a shift to glucose metabolism indicates dedifferentiation — poorer PRRT benefit; consider chemotherapy/biopsy.
Q3. Why is MAG3 preferred over DTPA in a poorly functioning kidney?
Answer: MAG3 is actively secreted (high extraction), giving usable images at low function, whereas filtered DTPA yields poor target-to-background in CKD.
Q4. What single chemical feature makes metal-based theranostic pairs (e.g. Ga-68/Lu-177) interchangeable at near-identical biodistribution?
Answer: A shared bifunctional chelator (DOTA) that binds either a diagnostic or a therapeutic radiometal on the same targeting ligand.
Evidence & sources
https://nuc.med/radiopharmaceutical-targets-mechanisms/ Report an issue